Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Exact Sciences Corporation

Market Cap 20.03B 17.45B 16.08B 15.13B 28.3B 1,887B 28.5B 191B 74.32B 930B 75.17B 73.56B 3,224B P/E 2024
-10.1x
P/E 2025 -92.2x
Enterprise Value 21.6B 18.82B 17.35B 16.32B 30.52B 2,035B 30.74B 206B 80.15B 1,003B 81.06B 79.32B 3,477B EV / Sales 2024
4.4x
EV / Sales 2025 6.42x
Free-Float
98.24%
Yield 2024 *
-
Yield 2025 -
1 day+0.95%
3 months+1.12%
6 months+3.48%
Current year+3.30%
Current year 101.51
Extreme 101.51
104.98
1 year 38.81
Extreme 38.8118
104.98
3 years 38.81
Extreme 38.8118
104.98
5 years 29.27
Extreme 29.27
133.99
10 years 9.91
Extreme 9.91
159.54
Date Insider Type Main position Quantity % Market Cap.
Mar. 22Free

Chief Executive Officer

2,533,955 1.3275%
Mar. 22Issuer sale

General Counsel

93,932 0.0492%
Mar. 22Free

Chief Financial Officer

261,465 0.1370%
Change 5-day change 1-year change 3-year change Capi.($)
+0.95%-.--%+100.44%+12.30% 20.03B
+4.56%+13.10%+99.96%+105.56% 4.09B
+4.47%-6.41%+67.43%+108.94% 2.69B
+3.92%+8.03%-27.48%-39.09% 1.94B
-0.51%-1.26%+91.67%-51.85% 1.75B
+11.50%+10.65%+37.57%+228.89% 1.21B
-2.37%+2.31%-14.79%+20.75% 898M
-0.38%-0.19%+158.71%-62.26% 770M
-10.05%-14.84%+61.92% - 746M
-1.73%-5.25%-31.30%-18.63% 518M
Average +0.62%+0.52%+54.41%+33.85% 3.46B
Weighted average by Cap. +1.23%+1.31%+83.52%+30.76%

Financials

2024 2025
Net sales 2.76B 2.4B 2.22B 2.08B 3.9B 260B 3.93B 26.36B 10.24B 128B 10.36B 10.13B 444B 3.25B 2.83B 2.61B 2.45B 4.59B 306B 4.62B 31.03B 12.05B 151B 12.19B 11.93B 523B
Net income -1.03B -896M -826M -777M -1.45B -96.97B -1.46B -9.83B -3.82B -47.79B -3.86B -3.78B -166B -208M -181M -167M -157M -294M -19.6B -296M -1.99B -772M -9.66B -781M -764M -33.48B
Net Debt 1.74B 1.51B 1.4B 1.31B 2.46B 164B 2.47B 16.61B 6.45B 80.71B 6.52B 6.38B 280B 1.57B 1.37B 1.26B 1.19B 2.22B 148B 2.23B 15B 5.83B 72.92B 5.89B 5.77B 253B
Logo Exact Sciences Corporation
Exact Sciences Corporation is a provider of cancer screening and diagnostic tests. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. It is focusing its research and development efforts on three main areas: Colorectal Cancer Screening Test Development, MCED Test Development and MRD Test Development. Its products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test, and Riskguard Test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.
Employees
7,150
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
AAA
  1. Stock Market
  2. Stocks
  3. EXAS Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!